1889. Poor immunogenicity of one-dose 13-valent pneumococcal conjugated vaccine in hematopoietic stem cell transplantation recipients
Session: Poster Abstract Session: Vaccines: PCV
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • HSCT PCV13.pdf (468.4 kB)
  • Background: Hematopoietic stem cell transplantation (HSCT) recipients were at significant risk for invasive pneumococcal disease while no study evaluated the immunogenicity of 1-dose 13-valent pneumococcal conjugated vaccine (PCV13) in this setting.

    Methods: HSCT recipients naïve for pneumococcal vaccine received 1-dose PCV13 at least 3 months after HSCT. Anti-capsular antibody responses against 4 serotypes (6B, 14, 19F and 23F) at baseline and 1, 3, 6, 9, and 12 months following vaccination were measured. Significant antibody responses were defined as 2-fold or greater increase of antibody levels compared with the baseline level.

    Results: From May 2014 to Apr 2015, a total of 40 HSCT recipients with a median age of 43.5 (IQR 35-53) were enrolled for 1-dose PCV13 after a median interval of 212.5 (IQR 126-355) days post-HSCT. Acute myeloid leukemia (28%) and lymphoma (28%) were the predominant underlying diseases. Of 32 patients with available antibody responses, significant responses against 6B, 14, 19F and 23F were observed in 9.4%, 31.2%, 12.5%, and 15.6% with geometric mean of 0.77, 4.86, 1.67, and 0.72 microgram/mL, respectively, 1-month post PCV13; 16% (4/25), 28% (7/25), 24% (6/25), and 24% (6/25) with geometric mean of 0.82, 4.74, 1.66, 0.6 microgram/mL, respectively, 3-months post PCV13, and all 42.9% (3/7) with geometric mean of 1.17, 8.07, 2.10, 0.95 microgram/mL, respectively, 6-months post PCV13.

    Conclusion: One-does PCV13 might be insufficient for HSCT recipients, and more doses of PCV13 might be needed.

    Hsin-Yun Sun, MD, Jia-Hau Liu, MD, Bor-Sheng Ko, MD, Chi-Cheng Li, MD, Ming Yao, MD, Jih-Lu Tang, MD and Wang-Huei Sheng, PhD, Internal Medicine, Natl Taiwan Univ Hosp, Taipei, Taiwan

    Disclosures:

    H. Y. Sun, None

    J. H. Liu, None

    B. S. Ko, None

    C. C. Li, None

    M. Yao, None

    J. L. Tang, None

    W. H. Sheng, None

    See more of: Vaccines: PCV
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.